CBER cell therapies office director
Executive Summary
FDA names former Intronn COO Edward Otto, PhD, director of the Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies, effective Nov. 14. Deputy Director Joyce Frey-Vasconcells, PhD, has served as acting director of CBER's cell therapies office since May after Acting Director Phil Noguchi, MD, moved temporarily to the Office of Orphan Products Development. Noguchi left FDA at the end of August to join Amgen (1"The Pink Sheet" Sept. 27, 2004, In Brief)...
You may also be interested in...
FDA gene therapy office director
Center for Biologics Evaluation & Research's Office of Cellular, Tissue & Gene Therapies' new director is Celia Witten. She was previously head of the Center for Devices & Radiological Health's Division of General, Restorative & Neurological Devices. The gene therapy office had been headed by former Intronn COO Edward Otto, who joined in November (1"The Pink Sheet" Nov. 1, 2004, In Brief). Otto left "to pursue outside interests," the agency said. Witten assumed her new role March 7...
Amgen regulatory affairs director
Former FDA Office of Cellular, Tissues & Gene Therapies Acting Director Philip Noguchi, MD, joins Amgen. Noguchi will be regulatory affairs director, responsible for the company's regulatory and clinical development policy. Also joining Amgen's Washington D.C. office is former Baxter VP-Government Affairs & Public Policy Jonathon Spear. Spear will be VP-public policy and will work to define strategic public policy options...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.